Navigation Links
DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
Date:2/17/2010

CUPERTINO, Calif., Feb. 17 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, March 24, 2010 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo:  http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR™, and TRANSDUR™-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR™, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation

RELATED LINKS
http://www.durect.com

'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
10. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
11. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... Radiology has become the number one diagnostic ... spiraled to the number one ranking as a result.  ... before as the most complete and reliable method for ... back pain an MRI may confirm a suspected herniated ... in entirely different treatment protocols.  In these circumstances, patients ...
(Date:5/9/2017)...  Demonstrating its commitment to representing research- based ... Pharmaceutical Research and Manufacturers of America (PhRMA) today ... now have to meet new research and development ... join PhRMA. "By putting in place ... clear message that being a member of PhRMA ...
(Date:5/8/2017)... YORK , May 8, 2017 ... the transition from fee for service reimbursement. Black Book ... 2017. 1.       The Market for MIPS ... 77% of physician practices with 3 or more ... Technology Solutions by Q4. "Given the magnitude of the ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Technique, technique, technique – with a dash ... weights for strength training and exercise or simply lifting heavy objects, advises Dr. Kaliq ... is everything,” Dr. Chang says. “Improper technique in lifting anything heavy or an attempt ...
(Date:5/23/2017)... New York City (PRWEB) , ... May 23, ... ... Record (EHR), Population Health and Clinical Integration company, announced today that its ... Patient-Centered Medical Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards ...
(Date:5/23/2017)... PITTSBURGH, Pa. (PRWEB) , ... May 23, 2017 , ... ... today plans to open The Alexis Joy D’Achille Center for Women’s Behavioral Health at ... state-of-the-art care available in western Pennsylvania for women suffering from pregnancy-related depression. Construction ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... North Carolina have remained steady since 2009, according to a Workers Compensation Research ... The study Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i Population ... Best in KLAS category winner, has named Daniel P. Bullington as chief technology ... its technology platform and product offerings,” says Justin Neece, president. “Daniel is an ...
Breaking Medicine News(10 mins):